| Literature DB >> 33557413 |
Erica Sarchielli1, Paolo Comeglio2, Sandra Filippi3, Ilaria Cellai2, Giulia Guarnieri1, Alessandra Marzoppi2, Sarah Cipriani2, Linda Vignozzi2,4, Annamaria Morelli1, Mario Maggi4,5.
Abstract
Metabolic syndrome (MetS) is known to be associated to inflammation and alteration in the hypothalamus, a brain region implicated in the control of several physiological functions, including energy homeostasis and reproduction. Previous studies demonstrated the beneficial effects of testosterone treatment (TTh) in counteracting some MetS symptoms in both animal models and clinical studies. This study investigated the effect of TTh (30 mg/kg/week for 12 weeks) on the hypothalamus in a high-fat diet (HFD)-induced animal model of MetS, utilizing quantitative RT-PCR and immunohistochemical analyses. The animal model recapitulates the human MetS features, including low testosterone/gonadotropin plasma levels. TTh significantly improved MetS-induced hypertension, visceral adipose tissue accumulation, and glucose homeostasis derangements. Within hypothalamus, TTh significantly counteracted HFD-induced inflammation, as detected in terms of expression of inflammatory markers and microglial activation. Moreover, TTh remarkably reverted the HFD-associated alterations in the expression of important regulators of energy status and reproduction, such as the melanocortin and the GnRH-controlling network. Our results suggest that TTh may exert neuroprotective effects on the HFD-related hypothalamic alterations, with positive outcomes on the circuits implicated in the control of energy metabolism and reproductive tasks, thus supporting a possible role of TTh in the clinical management of MetS.Entities:
Keywords: hypogonadotropic hypogonadism; hypothalamus; inflammation; metabolic syndrome; testosterone treatment
Mesh:
Substances:
Year: 2021 PMID: 33557413 PMCID: PMC7914611 DOI: 10.3390/ijms22041589
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923